Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ependymoma | 16 | 2023 | 320 | 4.090 |
Why?
|
Medulloblastoma | 22 | 2022 | 677 | 3.600 |
Why?
|
Cerebellar Neoplasms | 18 | 2022 | 585 | 3.530 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 14 | 2022 | 493 | 3.440 |
Why?
|
Brain Neoplasms | 37 | 2024 | 8984 | 2.300 |
Why?
|
Photons | 16 | 2022 | 581 | 2.270 |
Why?
|
Protons | 24 | 2024 | 1113 | 2.180 |
Why?
|
Chordoma | 6 | 2024 | 346 | 2.070 |
Why?
|
Radiotherapy Dosage | 44 | 2024 | 2897 | 1.960 |
Why?
|
Lymphokines | 19 | 2001 | 929 | 1.800 |
Why?
|
Germinoma | 8 | 2022 | 132 | 1.780 |
Why?
|
Radiotherapy, Conformal | 12 | 2018 | 549 | 1.620 |
Why?
|
Spinal Cord Neoplasms | 5 | 2023 | 264 | 1.600 |
Why?
|
Central Nervous System Neoplasms | 8 | 2022 | 917 | 1.570 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 25 | 2024 | 1660 | 1.550 |
Why?
|
Histamine Release | 17 | 2001 | 137 | 1.550 |
Why?
|
Radiotherapy, Intensity-Modulated | 13 | 2023 | 801 | 1.480 |
Why?
|
Breast Neoplasms | 41 | 2024 | 21065 | 1.470 |
Why?
|
Thoracic Wall | 6 | 2019 | 199 | 1.410 |
Why?
|
Skull Base Neoplasms | 3 | 2024 | 269 | 1.400 |
Why?
|
Relative Biological Effectiveness | 14 | 2021 | 312 | 1.360 |
Why?
|
Cranial Irradiation | 8 | 2022 | 391 | 1.180 |
Why?
|
Linear Energy Transfer | 7 | 2021 | 152 | 1.160 |
Why?
|
Chondrosarcoma | 3 | 2024 | 296 | 1.110 |
Why?
|
Pineal Gland | 4 | 2022 | 157 | 1.060 |
Why?
|
Basophils | 15 | 2001 | 405 | 1.010 |
Why?
|
Neoplasms, Second Primary | 4 | 2019 | 1060 | 0.910 |
Why?
|
Immunoglobulin E | 15 | 2001 | 1493 | 0.910 |
Why?
|
Radiation Injuries | 11 | 2022 | 1183 | 0.880 |
Why?
|
Sturge-Weber Syndrome | 2 | 2022 | 85 | 0.860 |
Why?
|
Choroid Neoplasms | 2 | 2022 | 177 | 0.860 |
Why?
|
Testicular Neoplasms | 5 | 2022 | 800 | 0.850 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2019 | 549 | 0.830 |
Why?
|
Spinal Neoplasms | 5 | 2024 | 716 | 0.830 |
Why?
|
Child | 81 | 2024 | 79758 | 0.810 |
Why?
|
Organs at Risk | 13 | 2023 | 358 | 0.800 |
Why?
|
Brain Stem | 6 | 2022 | 857 | 0.780 |
Why?
|
Child, Preschool | 57 | 2024 | 42034 | 0.770 |
Why?
|
Olfaction Disorders | 1 | 2024 | 224 | 0.760 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2024 | 9274 | 0.750 |
Why?
|
Hemangioma | 3 | 2022 | 727 | 0.720 |
Why?
|
Rehabilitation | 1 | 2021 | 129 | 0.710 |
Why?
|
Radiation Oncology | 2 | 2024 | 563 | 0.700 |
Why?
|
Lymphatic Metastasis | 6 | 2016 | 2945 | 0.680 |
Why?
|
Infratentorial Neoplasms | 5 | 2018 | 98 | 0.620 |
Why?
|
Mastectomy | 10 | 2019 | 1834 | 0.610 |
Why?
|
Supratentorial Neoplasms | 3 | 2013 | 159 | 0.600 |
Why?
|
Lymphatic Irradiation | 5 | 2024 | 115 | 0.600 |
Why?
|
Professional-Patient Relations | 1 | 2022 | 725 | 0.570 |
Why?
|
Hemangiosarcoma | 1 | 2019 | 218 | 0.560 |
Why?
|
Retinoblastoma | 3 | 2014 | 317 | 0.560 |
Why?
|
Adolescent | 55 | 2024 | 87747 | 0.560 |
Why?
|
Humans | 184 | 2024 | 760261 | 0.560 |
Why?
|
Hematologic Diseases | 1 | 2020 | 497 | 0.550 |
Why?
|
Radiotherapy | 5 | 2019 | 1505 | 0.540 |
Why?
|
Teratoma | 3 | 2022 | 403 | 0.540 |
Why?
|
Community Health Services | 1 | 2021 | 654 | 0.530 |
Why?
|
Gynecomastia | 1 | 2016 | 87 | 0.530 |
Why?
|
Telemedicine | 2 | 2024 | 3005 | 0.530 |
Why?
|
Glioma | 7 | 2020 | 3420 | 0.520 |
Why?
|
Radiotherapy, High-Energy | 2 | 2007 | 228 | 0.520 |
Why?
|
Pituitary Neoplasms | 2 | 2021 | 1313 | 0.510 |
Why?
|
Carotid Stenosis | 1 | 2023 | 872 | 0.500 |
Why?
|
Young Adult | 43 | 2024 | 58673 | 0.500 |
Why?
|
Scattering, Radiation | 1 | 2017 | 488 | 0.490 |
Why?
|
Infant | 31 | 2024 | 36030 | 0.490 |
Why?
|
Radiodermatitis | 3 | 2014 | 58 | 0.480 |
Why?
|
Lymph Nodes | 4 | 2019 | 3491 | 0.470 |
Why?
|
Quality-Adjusted Life Years | 3 | 2016 | 1724 | 0.450 |
Why?
|
Breast | 7 | 2021 | 1980 | 0.450 |
Why?
|
Pituitary Gland, Posterior | 1 | 2013 | 42 | 0.440 |
Why?
|
Spine | 2 | 2019 | 1111 | 0.440 |
Why?
|
Monte Carlo Method | 8 | 2020 | 1256 | 0.440 |
Why?
|
Female | 102 | 2024 | 391011 | 0.430 |
Why?
|
Delayed Diagnosis | 2 | 2016 | 463 | 0.430 |
Why?
|
Sarcoma | 1 | 2024 | 1786 | 0.420 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2013 | 136 | 0.410 |
Why?
|
Rhabdoid Tumor | 2 | 2017 | 210 | 0.400 |
Why?
|
Mammaplasty | 4 | 2019 | 1239 | 0.390 |
Why?
|
Spinal Cord | 2 | 2021 | 1817 | 0.390 |
Why?
|
Automobile Driving | 1 | 2017 | 438 | 0.390 |
Why?
|
Vomiting | 4 | 2024 | 649 | 0.380 |
Why?
|
Treatment Outcome | 36 | 2024 | 64947 | 0.380 |
Why?
|
Hippocampus | 4 | 2022 | 3737 | 0.370 |
Why?
|
Radiometry | 6 | 2018 | 813 | 0.360 |
Why?
|
Combined Modality Therapy | 14 | 2022 | 8551 | 0.360 |
Why?
|
Head and Neck Neoplasms | 2 | 2023 | 2880 | 0.350 |
Why?
|
Hypogonadism | 1 | 2016 | 800 | 0.350 |
Why?
|
Male | 73 | 2024 | 359413 | 0.350 |
Why?
|
Neuroblastoma | 2 | 2024 | 1252 | 0.350 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2014 | 586 | 0.350 |
Why?
|
Retrospective Studies | 32 | 2024 | 80301 | 0.350 |
Why?
|
Rhabdomyosarcoma | 4 | 2014 | 361 | 0.340 |
Why?
|
Nausea | 2 | 2024 | 677 | 0.330 |
Why?
|
Craniopharyngioma | 3 | 2021 | 277 | 0.330 |
Why?
|
Tumor Burden | 8 | 2021 | 1897 | 0.330 |
Why?
|
Cost Savings | 1 | 2015 | 920 | 0.330 |
Why?
|
Neoplasms | 9 | 2024 | 22066 | 0.330 |
Why?
|
Radiotherapy, Adjuvant | 10 | 2021 | 1790 | 0.320 |
Why?
|
Treatment Failure | 6 | 2022 | 2646 | 0.310 |
Why?
|
Mastectomy, Segmental | 7 | 2015 | 965 | 0.310 |
Why?
|
Moyamoya Disease | 2 | 2022 | 255 | 0.310 |
Why?
|
Central Nervous System | 3 | 2022 | 1334 | 0.310 |
Why?
|
Dose-Response Relationship, Radiation | 6 | 2022 | 881 | 0.300 |
Why?
|
Sacrum | 3 | 2024 | 281 | 0.290 |
Why?
|
Radiation Dosage | 5 | 2024 | 1957 | 0.280 |
Why?
|
Breast Implants | 3 | 2019 | 411 | 0.270 |
Why?
|
Follow-Up Studies | 20 | 2023 | 39254 | 0.270 |
Why?
|
Interleukin-4 | 4 | 1997 | 1133 | 0.260 |
Why?
|
Immobilization | 1 | 2007 | 230 | 0.260 |
Why?
|
Recombinant Proteins | 11 | 2005 | 6543 | 0.260 |
Why?
|
Disease-Free Survival | 10 | 2022 | 6830 | 0.260 |
Why?
|
Gastroenteritis | 2 | 2019 | 237 | 0.260 |
Why?
|
Adult | 45 | 2024 | 219847 | 0.250 |
Why?
|
Cost-Benefit Analysis | 6 | 2021 | 5507 | 0.250 |
Why?
|
Prospective Studies | 20 | 2024 | 54263 | 0.250 |
Why?
|
Antibodies, Anti-Idiotypic | 6 | 1999 | 357 | 0.250 |
Why?
|
Heart | 3 | 2017 | 4392 | 0.230 |
Why?
|
Fetal Proteins | 1 | 2024 | 97 | 0.230 |
Why?
|
Stroke | 2 | 2023 | 9945 | 0.220 |
Why?
|
Omentum | 1 | 2024 | 169 | 0.220 |
Why?
|
Mastectomy, Modified Radical | 3 | 2015 | 62 | 0.220 |
Why?
|
Surgical Flaps | 2 | 2024 | 1666 | 0.220 |
Why?
|
Fatigue | 3 | 2024 | 1544 | 0.210 |
Why?
|
Radiography | 5 | 2015 | 6965 | 0.210 |
Why?
|
Retinal Neoplasms | 2 | 2014 | 146 | 0.200 |
Why?
|
Models, Economic | 3 | 2015 | 719 | 0.200 |
Why?
|
Granular Cell Tumor | 1 | 2022 | 48 | 0.200 |
Why?
|
Postoperative Care | 3 | 2018 | 1478 | 0.190 |
Why?
|
Magnetic Resonance Imaging | 10 | 2022 | 36247 | 0.190 |
Why?
|
Carboplatin | 2 | 2022 | 789 | 0.190 |
Why?
|
Fibrosarcoma | 1 | 2023 | 308 | 0.180 |
Why?
|
Interleukin-8 | 2 | 2001 | 698 | 0.180 |
Why?
|
Skull Base | 1 | 2023 | 291 | 0.180 |
Why?
|
Molecular Mimicry | 1 | 2001 | 200 | 0.180 |
Why?
|
Vincristine | 2 | 2020 | 1038 | 0.180 |
Why?
|
Evidence-Based Medicine | 2 | 2012 | 3696 | 0.180 |
Why?
|
Grief | 1 | 2022 | 254 | 0.180 |
Why?
|
Hypersensitivity, Immediate | 2 | 2001 | 345 | 0.170 |
Why?
|
Program Evaluation | 2 | 2021 | 2494 | 0.170 |
Why?
|
Orbital Neoplasms | 1 | 2022 | 221 | 0.170 |
Why?
|
Blood Cell Count | 1 | 2020 | 398 | 0.170 |
Why?
|
Quality of Life | 8 | 2024 | 13300 | 0.170 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2001 | 414 | 0.170 |
Why?
|
Radiobiology | 1 | 2020 | 89 | 0.170 |
Why?
|
Peer Review | 1 | 2021 | 218 | 0.160 |
Why?
|
Vaccines | 2 | 2017 | 833 | 0.160 |
Why?
|
Age Factors | 9 | 2021 | 18415 | 0.160 |
Why?
|
Eosinophils | 2 | 2001 | 946 | 0.160 |
Why?
|
Pediatrics | 4 | 2020 | 3587 | 0.160 |
Why?
|
Cognition | 6 | 2021 | 6948 | 0.160 |
Why?
|
Tattooing | 1 | 2019 | 57 | 0.160 |
Why?
|
Lymphopenia | 1 | 2021 | 280 | 0.160 |
Why?
|
Retinal Pigments | 1 | 1998 | 83 | 0.160 |
Why?
|
Rib Fractures | 1 | 2020 | 130 | 0.160 |
Why?
|
Aged | 22 | 2024 | 168995 | 0.160 |
Why?
|
Middle Aged | 31 | 2024 | 220175 | 0.160 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2022 | 2129 | 0.160 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 1999 | 194 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 11708 | 0.150 |
Why?
|
Skull | 1 | 2023 | 815 | 0.150 |
Why?
|
Patient Positioning | 2 | 2018 | 327 | 0.150 |
Why?
|
Pituitary Gland | 2 | 2018 | 637 | 0.150 |
Why?
|
Intelligence | 3 | 2018 | 919 | 0.150 |
Why?
|
Nanoparticles | 1 | 2009 | 1938 | 0.150 |
Why?
|
Feasibility Studies | 4 | 2019 | 5201 | 0.150 |
Why?
|
Wechsler Scales | 1 | 2018 | 257 | 0.150 |
Why?
|
Dark Adaptation | 1 | 1998 | 221 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6545 | 0.150 |
Why?
|
Growth Disorders | 1 | 2022 | 654 | 0.140 |
Why?
|
Growth Plate | 2 | 2017 | 275 | 0.140 |
Why?
|
Independent Living | 1 | 2021 | 568 | 0.140 |
Why?
|
Contrast Sensitivity | 1 | 1998 | 235 | 0.140 |
Why?
|
Consensus | 3 | 2022 | 3106 | 0.140 |
Why?
|
Cohort Studies | 12 | 2022 | 41317 | 0.140 |
Why?
|
Chemokine CCL2 | 2 | 1996 | 607 | 0.140 |
Why?
|
Prognosis | 12 | 2023 | 29636 | 0.140 |
Why?
|
Rhabdomyosarcoma, Embryonal | 2 | 2015 | 101 | 0.140 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 625 | 0.140 |
Why?
|
Time Factors | 9 | 2021 | 40133 | 0.140 |
Why?
|
Cost Allocation | 1 | 2016 | 50 | 0.130 |
Why?
|
Practice Guidelines as Topic | 3 | 2018 | 7468 | 0.130 |
Why?
|
Survivors | 4 | 2020 | 2367 | 0.130 |
Why?
|
Diabetes Insipidus | 1 | 2016 | 144 | 0.130 |
Why?
|
Paraplegia | 1 | 2016 | 162 | 0.130 |
Why?
|
Vaccination | 2 | 2019 | 3360 | 0.130 |
Why?
|
Bone Neoplasms | 2 | 2023 | 2532 | 0.130 |
Why?
|
Meningeal Neoplasms | 3 | 2015 | 1248 | 0.130 |
Why?
|
Models, Econometric | 1 | 2016 | 216 | 0.130 |
Why?
|
Forecasting | 1 | 2024 | 2931 | 0.130 |
Why?
|
Endocrine System Diseases | 2 | 2018 | 251 | 0.130 |
Why?
|
Testis | 2 | 2016 | 794 | 0.120 |
Why?
|
alpha-Fetoproteins | 2 | 2013 | 222 | 0.120 |
Why?
|
Interleukin-13 | 1 | 1997 | 371 | 0.120 |
Why?
|
Endocrine System | 1 | 2015 | 112 | 0.120 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 582 | 0.120 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2015 | 58 | 0.120 |
Why?
|
Cold Temperature | 1 | 1998 | 780 | 0.120 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2020 | 470 | 0.120 |
Why?
|
Lectins | 1 | 1996 | 485 | 0.120 |
Why?
|
Antineoplastic Agents | 5 | 2016 | 13629 | 0.120 |
Why?
|
Alberta | 3 | 2019 | 66 | 0.120 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 507 | 0.110 |
Why?
|
Self Care | 1 | 2019 | 793 | 0.110 |
Why?
|
Calcium-Binding Proteins | 1 | 1999 | 1066 | 0.110 |
Why?
|
Astrocytoma | 1 | 2018 | 775 | 0.110 |
Why?
|
Disability Evaluation | 1 | 2021 | 1826 | 0.110 |
Why?
|
Down Syndrome | 1 | 2022 | 891 | 0.110 |
Why?
|
Vision Disorders | 1 | 2021 | 1084 | 0.110 |
Why?
|
Hypothalamus | 1 | 2018 | 998 | 0.110 |
Why?
|
Malaria, Falciparum | 1 | 2001 | 1076 | 0.110 |
Why?
|
Nasal Cavity | 1 | 2015 | 304 | 0.110 |
Why?
|
Headache | 1 | 2021 | 1249 | 0.110 |
Why?
|
Nose Neoplasms | 1 | 2015 | 249 | 0.110 |
Why?
|
Interleukin-3 | 2 | 1996 | 429 | 0.100 |
Why?
|
Memory | 2 | 2019 | 2179 | 0.100 |
Why?
|
Pelvic Neoplasms | 1 | 2014 | 248 | 0.100 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 1008 | 0.100 |
Why?
|
Markov Chains | 1 | 2016 | 971 | 0.100 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 102 | 0.100 |
Why?
|
Thoracic Neoplasms | 1 | 2014 | 265 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2019 | 14482 | 0.100 |
Why?
|
Incidence | 5 | 2022 | 21378 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2019 | 1094 | 0.100 |
Why?
|
Dose-Response Relationship, Immunologic | 4 | 1999 | 366 | 0.100 |
Why?
|
Choice Behavior | 1 | 2017 | 817 | 0.100 |
Why?
|
Parents | 4 | 2019 | 3547 | 0.100 |
Why?
|
Plasmodium falciparum | 1 | 2001 | 1741 | 0.100 |
Why?
|
Uveal Neoplasms | 1 | 2014 | 339 | 0.100 |
Why?
|
Communicable Disease Control | 1 | 2017 | 844 | 0.090 |
Why?
|
Chorionic Gonadotropin | 1 | 2013 | 457 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2016 | 3531 | 0.090 |
Why?
|
Esophagus | 1 | 2017 | 1023 | 0.090 |
Why?
|
Neoplasm Staging | 7 | 2017 | 11141 | 0.090 |
Why?
|
Memory Disorders | 1 | 2018 | 1197 | 0.090 |
Why?
|
Medical Oncology | 1 | 2022 | 2321 | 0.090 |
Why?
|
Intestine, Small | 1 | 2017 | 1207 | 0.090 |
Why?
|
Catheterization | 1 | 2016 | 1432 | 0.090 |
Why?
|
Breast Diseases | 1 | 2014 | 443 | 0.090 |
Why?
|
Patient Preference | 1 | 2017 | 921 | 0.090 |
Why?
|
Alopecia | 1 | 2014 | 415 | 0.090 |
Why?
|
Thyroid Gland | 1 | 2017 | 1169 | 0.090 |
Why?
|
Photography | 1 | 2013 | 530 | 0.090 |
Why?
|
Attitude to Health | 1 | 2019 | 2028 | 0.090 |
Why?
|
Aged, 80 and over | 10 | 2024 | 58947 | 0.080 |
Why?
|
Canada | 4 | 2019 | 2128 | 0.080 |
Why?
|
Recovery of Function | 2 | 2016 | 2982 | 0.080 |
Why?
|
Lymph Node Excision | 5 | 2015 | 1305 | 0.080 |
Why?
|
Cervical Vertebrae | 1 | 2015 | 978 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2000 | 4357 | 0.080 |
Why?
|
Life Expectancy | 1 | 2016 | 1249 | 0.080 |
Why?
|
Clinical Clerkship | 1 | 2015 | 563 | 0.080 |
Why?
|
Executive Function | 1 | 2017 | 1370 | 0.080 |
Why?
|
Motivation | 1 | 2019 | 1990 | 0.080 |
Why?
|
Optic Chiasm | 2 | 2022 | 91 | 0.080 |
Why?
|
Radiosurgery | 1 | 2018 | 1343 | 0.080 |
Why?
|
Lung | 4 | 2018 | 9989 | 0.080 |
Why?
|
Ferrosoferric Oxide | 1 | 2009 | 348 | 0.080 |
Why?
|
Cerebellum | 1 | 2015 | 1495 | 0.080 |
Why?
|
SEER Program | 1 | 2013 | 1532 | 0.080 |
Why?
|
Mothers | 1 | 2019 | 2186 | 0.080 |
Why?
|
Echocardiography | 2 | 2022 | 4980 | 0.080 |
Why?
|
Sepsis | 1 | 2022 | 2594 | 0.080 |
Why?
|
Neuropsychological Tests | 3 | 2018 | 7016 | 0.070 |
Why?
|
Magnetite Nanoparticles | 1 | 2009 | 316 | 0.070 |
Why?
|
Skin | 3 | 2014 | 4468 | 0.070 |
Why?
|
Creatine Kinase, MB Form | 1 | 2008 | 211 | 0.070 |
Why?
|
Etoposide | 2 | 2022 | 630 | 0.070 |
Why?
|
Dextrans | 1 | 2009 | 574 | 0.070 |
Why?
|
Vacuum | 1 | 2007 | 66 | 0.070 |
Why?
|
Recurrence | 2 | 2023 | 8487 | 0.070 |
Why?
|
Analysis of Variance | 4 | 2018 | 6242 | 0.070 |
Why?
|
Lymphedema | 1 | 2014 | 525 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1363 | 0.070 |
Why?
|
Biopsy | 1 | 2019 | 6775 | 0.070 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2013 | 781 | 0.070 |
Why?
|
Axilla | 3 | 2015 | 618 | 0.070 |
Why?
|
Receptor, erbB-2 | 2 | 2016 | 2544 | 0.070 |
Why?
|
Body Height | 1 | 2013 | 1570 | 0.070 |
Why?
|
4-Aminobenzoic Acid | 1 | 2006 | 22 | 0.070 |
Why?
|
Decision Support Systems, Clinical | 1 | 2016 | 1162 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 1999 | 3613 | 0.070 |
Why?
|
Confidence Intervals | 3 | 2017 | 2932 | 0.070 |
Why?
|
Cause of Death | 2 | 2014 | 3723 | 0.070 |
Why?
|
Prone Position | 1 | 2007 | 196 | 0.070 |
Why?
|
Thymus Neoplasms | 1 | 2008 | 274 | 0.060 |
Why?
|
Salvage Therapy | 1 | 2012 | 1266 | 0.060 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 3764 | 0.060 |
Why?
|
International Agencies | 2 | 2017 | 244 | 0.060 |
Why?
|
Decision Making | 1 | 2019 | 3924 | 0.060 |
Why?
|
Collagen Type IV | 1 | 2005 | 127 | 0.060 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2011 | 938 | 0.060 |
Why?
|
Necrosis | 2 | 2019 | 1612 | 0.060 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2006 | 345 | 0.060 |
Why?
|
Lymphoma | 1 | 2013 | 1899 | 0.060 |
Why?
|
Heart Diseases | 1 | 1997 | 2809 | 0.060 |
Why?
|
Brachytherapy | 1 | 2011 | 1240 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3159 | 0.060 |
Why?
|
Immunization, Passive | 2 | 1996 | 616 | 0.060 |
Why?
|
Seizures | 1 | 2016 | 2916 | 0.060 |
Why?
|
Disease Progression | 5 | 2021 | 13505 | 0.060 |
Why?
|
Cells, Cultured | 4 | 2001 | 18968 | 0.060 |
Why?
|
Risk Factors | 8 | 2019 | 74269 | 0.050 |
Why?
|
Troponin T | 1 | 2008 | 774 | 0.050 |
Why?
|
Fat Necrosis | 2 | 2014 | 60 | 0.050 |
Why?
|
Peptide Fragments | 2 | 2022 | 5120 | 0.050 |
Why?
|
Neoadjuvant Therapy | 3 | 2022 | 2811 | 0.050 |
Why?
|
Melanocytes | 1 | 2006 | 512 | 0.050 |
Why?
|
Organ Size | 1 | 2008 | 2249 | 0.050 |
Why?
|
Circle of Willis | 1 | 2022 | 79 | 0.050 |
Why?
|
Survival Rate | 3 | 2013 | 12806 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8595 | 0.050 |
Why?
|
Palliative Care | 1 | 2017 | 3607 | 0.050 |
Why?
|
Students, Medical | 1 | 2015 | 1926 | 0.050 |
Why?
|
Enzyme Precursors | 1 | 2001 | 174 | 0.050 |
Why?
|
T-Box Domain Proteins | 1 | 2024 | 469 | 0.050 |
Why?
|
Glioblastoma | 1 | 2016 | 3482 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 7072 | 0.050 |
Why?
|
Coronary Disease | 1 | 2016 | 5993 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5396 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12968 | 0.050 |
Why?
|
Risk | 1 | 2013 | 9629 | 0.050 |
Why?
|
Liver | 1 | 2017 | 7512 | 0.050 |
Why?
|
Phosphatidylinositol Phosphates | 1 | 2001 | 202 | 0.050 |
Why?
|
Patient Satisfaction | 3 | 2024 | 3451 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14656 | 0.050 |
Why?
|
Diarrhea | 2 | 2019 | 1341 | 0.050 |
Why?
|
Visual Acuity | 3 | 2014 | 2635 | 0.040 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8058 | 0.040 |
Why?
|
Postoperative Period | 2 | 2016 | 1821 | 0.040 |
Why?
|
Cloning, Molecular | 2 | 1996 | 4172 | 0.040 |
Why?
|
Memory, Short-Term | 2 | 2017 | 977 | 0.040 |
Why?
|
Computer Simulation | 1 | 2013 | 6210 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7809 | 0.040 |
Why?
|
Carcinoma | 1 | 2011 | 2334 | 0.040 |
Why?
|
Infant, Newborn | 3 | 2017 | 26168 | 0.040 |
Why?
|
Caliciviridae Infections | 1 | 2019 | 29 | 0.040 |
Why?
|
Histamine | 1 | 2001 | 499 | 0.040 |
Why?
|
Norovirus | 1 | 2019 | 36 | 0.040 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2008 | 1705 | 0.040 |
Why?
|
Virulence Factors, Bordetella | 1 | 1999 | 154 | 0.040 |
Why?
|
Retinal Detachment | 2 | 2014 | 427 | 0.040 |
Why?
|
Pertussis Toxin | 1 | 1999 | 176 | 0.040 |
Why?
|
Culture Media | 1 | 2001 | 899 | 0.040 |
Why?
|
Acetophenones | 1 | 1999 | 53 | 0.040 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 1999 | 113 | 0.040 |
Why?
|
Benzopyrans | 1 | 1999 | 63 | 0.040 |
Why?
|
Seroma | 1 | 2019 | 76 | 0.040 |
Why?
|
src-Family Kinases | 1 | 2001 | 534 | 0.040 |
Why?
|
Rett Syndrome | 1 | 2000 | 164 | 0.040 |
Why?
|
Hybrid Cells | 1 | 1999 | 422 | 0.040 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2001 | 414 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2021 | 780 | 0.040 |
Why?
|
Troponin | 1 | 2022 | 516 | 0.040 |
Why?
|
Orbit | 1 | 2022 | 446 | 0.040 |
Why?
|
Staurosporine | 1 | 1999 | 242 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2019 | 156 | 0.040 |
Why?
|
Obesity | 2 | 1997 | 12915 | 0.040 |
Why?
|
Mammography | 1 | 2009 | 2452 | 0.040 |
Why?
|
Dehydration | 1 | 2019 | 226 | 0.040 |
Why?
|
Drug Synergism | 2 | 2000 | 1755 | 0.040 |
Why?
|
Kinetics | 2 | 1996 | 6378 | 0.040 |
Why?
|
Esophageal Neoplasms | 1 | 2008 | 1651 | 0.040 |
Why?
|
Dendrites | 1 | 2000 | 475 | 0.040 |
Why?
|
Oculomotor Muscles | 1 | 2022 | 407 | 0.040 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 489 | 0.040 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2010 | 2277 | 0.040 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2000 | 663 | 0.040 |
Why?
|
Carbazoles | 1 | 1999 | 221 | 0.040 |
Why?
|
Pneumonia | 1 | 2009 | 2138 | 0.040 |
Why?
|
Receptors, IgE | 1 | 1999 | 377 | 0.040 |
Why?
|
Survival Analysis | 3 | 2016 | 10185 | 0.040 |
Why?
|
Extracellular Matrix | 1 | 2005 | 1726 | 0.040 |
Why?
|
Sensory Thresholds | 1 | 1998 | 377 | 0.040 |
Why?
|
United States | 5 | 2019 | 72363 | 0.040 |
Why?
|
Texas | 1 | 2018 | 401 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 886 | 0.040 |
Why?
|
Risk Assessment | 4 | 2022 | 24086 | 0.040 |
Why?
|
Probability | 1 | 2022 | 2476 | 0.040 |
Why?
|
Body Constitution | 1 | 1997 | 273 | 0.040 |
Why?
|
Florida | 1 | 2018 | 427 | 0.030 |
Why?
|
Ischemic Attack, Transient | 1 | 2022 | 899 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2018 | 295 | 0.030 |
Why?
|
Acute Disease | 2 | 2019 | 7268 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2019 | 15680 | 0.030 |
Why?
|
Polymerase Chain Reaction | 3 | 2006 | 6067 | 0.030 |
Why?
|
Melanins | 1 | 1998 | 291 | 0.030 |
Why?
|
Contrast Media | 1 | 2009 | 5301 | 0.030 |
Why?
|
Cardiotoxins | 1 | 2016 | 37 | 0.030 |
Why?
|
Mannose | 1 | 1996 | 121 | 0.030 |
Why?
|
Base Sequence | 2 | 1999 | 12447 | 0.030 |
Why?
|
Telephone | 1 | 2019 | 623 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 629 | 0.030 |
Why?
|
Logistic Models | 2 | 2022 | 13311 | 0.030 |
Why?
|
Rural Health | 1 | 1997 | 299 | 0.030 |
Why?
|
Stroke Volume | 2 | 2022 | 5513 | 0.030 |
Why?
|
Calibration | 1 | 2018 | 816 | 0.030 |
Why?
|
Cerebrovascular Disorders | 1 | 2022 | 1500 | 0.030 |
Why?
|
Sex Distribution | 2 | 1997 | 2295 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 1998 | 1760 | 0.030 |
Why?
|
Elastic Modulus | 1 | 2016 | 210 | 0.030 |
Why?
|
Breast Implantation | 1 | 2018 | 223 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 425 | 0.030 |
Why?
|
Cricetinae | 1 | 1999 | 2427 | 0.030 |
Why?
|
Chromatography, Ion Exchange | 1 | 1995 | 297 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2015 | 251 | 0.030 |
Why?
|
Topotecan | 1 | 2015 | 132 | 0.030 |
Why?
|
Intention | 1 | 2017 | 337 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2000 | 1344 | 0.030 |
Why?
|
Cytokines | 1 | 1990 | 7345 | 0.030 |
Why?
|
Urban Health | 1 | 1997 | 533 | 0.030 |
Why?
|
Microbiological Techniques | 1 | 2015 | 98 | 0.030 |
Why?
|
Age Distribution | 2 | 1997 | 2893 | 0.030 |
Why?
|
Protein Kinase C | 1 | 1999 | 1201 | 0.030 |
Why?
|
DNA Primers | 1 | 1999 | 2819 | 0.030 |
Why?
|
Hematoma | 1 | 2019 | 769 | 0.030 |
Why?
|
Career Mobility | 1 | 1996 | 258 | 0.030 |
Why?
|
Regression Analysis | 2 | 2015 | 6361 | 0.030 |
Why?
|
Telangiectasis | 1 | 2014 | 77 | 0.030 |
Why?
|
Cell Line | 2 | 2000 | 15626 | 0.030 |
Why?
|
Animals | 8 | 2006 | 167940 | 0.030 |
Why?
|
Anthracyclines | 1 | 2016 | 283 | 0.030 |
Why?
|
Chromatography, Affinity | 1 | 1995 | 534 | 0.030 |
Why?
|
Prosthesis Failure | 1 | 2019 | 1206 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1723 | 0.030 |
Why?
|
Lymphocytes | 1 | 2001 | 2612 | 0.030 |
Why?
|
Mice | 6 | 2006 | 81216 | 0.030 |
Why?
|
Chick Embryo | 2 | 2006 | 981 | 0.030 |
Why?
|
Sex Factors | 3 | 2016 | 10530 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2006 | 3389 | 0.030 |
Why?
|
International Cooperation | 1 | 2020 | 1436 | 0.030 |
Why?
|
Cicatrix | 1 | 2019 | 781 | 0.030 |
Why?
|
Uncertainty | 1 | 2018 | 754 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2024 | 20048 | 0.030 |
Why?
|
Educational Status | 2 | 1997 | 2512 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 4 | 2018 | 20484 | 0.030 |
Why?
|
DNA, Complementary | 1 | 1996 | 1993 | 0.030 |
Why?
|
Triage | 1 | 2019 | 982 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2001 | 2415 | 0.030 |
Why?
|
Prejudice | 1 | 1996 | 563 | 0.030 |
Why?
|
Monocytes | 1 | 2001 | 2574 | 0.030 |
Why?
|
Erythrocytes | 1 | 2001 | 2415 | 0.030 |
Why?
|
Skin Pigmentation | 1 | 2014 | 277 | 0.020 |
Why?
|
Species Specificity | 1 | 1996 | 2413 | 0.020 |
Why?
|
Massachusetts | 2 | 2018 | 8805 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2018 | 1297 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2874 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 6131 | 0.020 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2011 | 42 | 0.020 |
Why?
|
Elasticity Imaging Techniques | 1 | 2016 | 389 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1995 | 2755 | 0.020 |
Why?
|
Indoles | 1 | 1999 | 1830 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12532 | 0.020 |
Why?
|
Specimen Handling | 1 | 2015 | 708 | 0.020 |
Why?
|
Melanoma | 2 | 2006 | 5695 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 1999 | 4625 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2019 | 1853 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2005 | 10829 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2008 | 22041 | 0.020 |
Why?
|
Esthetics | 1 | 2011 | 326 | 0.020 |
Why?
|
Comprehension | 1 | 2015 | 613 | 0.020 |
Why?
|
Body Mass Index | 3 | 2014 | 12901 | 0.020 |
Why?
|
Epitopes | 1 | 1996 | 2506 | 0.020 |
Why?
|
Brain | 1 | 2016 | 26912 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3870 | 0.020 |
Why?
|
Walking | 1 | 2016 | 1190 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2016 | 1295 | 0.020 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 1 | 1989 | 221 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2015 | 2220 | 0.020 |
Why?
|
Cisplatin | 1 | 2015 | 1642 | 0.020 |
Why?
|
Feces | 1 | 2015 | 1466 | 0.020 |
Why?
|
Femur Head | 1 | 2010 | 297 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 1999 | 3726 | 0.020 |
Why?
|
Lung Neoplasms | 2 | 2014 | 13249 | 0.020 |
Why?
|
Pelvic Bones | 1 | 2010 | 271 | 0.020 |
Why?
|
Doxorubicin | 1 | 2015 | 2207 | 0.020 |
Why?
|
Faculty, Medical | 1 | 1996 | 1192 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2022 | 3526 | 0.020 |
Why?
|
Social Support | 1 | 2017 | 2145 | 0.020 |
Why?
|
Hypersensitivity, Delayed | 1 | 1989 | 490 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3618 | 0.020 |
Why?
|
Glucocorticoids | 1 | 1997 | 2143 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2002 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2010 | 11341 | 0.020 |
Why?
|
World Health Organization | 1 | 2013 | 1319 | 0.020 |
Why?
|
Calcium | 1 | 2000 | 5726 | 0.020 |
Why?
|
Antibodies | 1 | 1995 | 2424 | 0.020 |
Why?
|
Plant Proteins | 1 | 1989 | 370 | 0.020 |
Why?
|
Qualitative Research | 1 | 2017 | 2958 | 0.020 |
Why?
|
Tamoxifen | 1 | 2011 | 963 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1995 | 3735 | 0.020 |
Why?
|
Temporal Lobe | 1 | 2014 | 1687 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2001 | 12762 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1344 | 0.020 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 1989 | 545 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 1996 | 2753 | 0.020 |
Why?
|
Interleukin-1 | 1 | 1989 | 1250 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12156 | 0.020 |
Why?
|
Dermatitis, Atopic | 1 | 1993 | 710 | 0.020 |
Why?
|
Cost of Illness | 1 | 2015 | 1940 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 358 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2006 | 22025 | 0.020 |
Why?
|
Health Expenditures | 1 | 2017 | 2359 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2017 | 3811 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2014 | 25928 | 0.010 |
Why?
|
Fibrosis | 1 | 2011 | 2042 | 0.010 |
Why?
|
Urinary Bladder | 1 | 2010 | 1166 | 0.010 |
Why?
|
Adjuvants, Immunologic | 1 | 1989 | 1041 | 0.010 |
Why?
|
Desensitization, Immunologic | 1 | 1989 | 532 | 0.010 |
Why?
|
Retina | 1 | 2014 | 2635 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1995 | 13456 | 0.010 |
Why?
|
Prevalence | 2 | 1997 | 15687 | 0.010 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2008 | 421 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 1523 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 3967 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1989 | 1558 | 0.010 |
Why?
|
Observer Variation | 1 | 2009 | 2596 | 0.010 |
Why?
|
Rats | 1 | 1999 | 23695 | 0.010 |
Why?
|
Registries | 1 | 2019 | 8449 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 1995 | 17628 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 10340 | 0.010 |
Why?
|
Allergens | 1 | 1989 | 1399 | 0.010 |
Why?
|
Curriculum | 1 | 2015 | 3722 | 0.010 |
Why?
|
Leukocytes | 1 | 1990 | 2030 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 1997 | 9196 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2005 | 2014 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2019 | 5324 | 0.010 |
Why?
|
Hypersensitivity | 1 | 1990 | 1159 | 0.010 |
Why?
|
Macrophages | 1 | 1995 | 5745 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5960 | 0.010 |
Why?
|
Apoptosis | 2 | 2006 | 9497 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2005 | 11064 | 0.010 |
Why?
|
Cell Line, Tumor | 2 | 2006 | 16905 | 0.010 |
Why?
|
Blotting, Western | 1 | 2006 | 5039 | 0.010 |
Why?
|
Mice, Nude | 1 | 2005 | 3605 | 0.010 |
Why?
|
Signal Transduction | 1 | 2001 | 23363 | 0.010 |
Why?
|
Neurofilament Proteins | 1 | 2000 | 333 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2005 | 3096 | 0.010 |
Why?
|
Ligands | 1 | 2005 | 3277 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2005 | 3800 | 0.010 |
Why?
|
Cell Communication | 1 | 2005 | 1642 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2005 | 2651 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15827 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2006 | 6226 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 29725 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2000 | 2262 | 0.010 |
Why?
|
Algorithms | 1 | 2016 | 13967 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15273 | 0.010 |
Why?
|
Microtubule-Associated Proteins | 1 | 2000 | 1078 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2006 | 10434 | 0.010 |
Why?
|
Poaceae | 1 | 1989 | 27 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5248 | 0.010 |
Why?
|
Pollen | 1 | 1989 | 82 | 0.010 |
Why?
|
Phosphorylation | 1 | 2000 | 8314 | 0.010 |
Why?
|
Antigens, Plant | 1 | 1989 | 105 | 0.010 |
Why?
|
Prostaglandin D2 | 1 | 1989 | 110 | 0.000 |
Why?
|
Income | 1 | 1997 | 1876 | 0.000 |
Why?
|
Skin Neoplasms | 1 | 2005 | 5797 | 0.000 |
Why?
|
Nose | 1 | 1989 | 519 | 0.000 |
Why?
|
Aging | 1 | 2000 | 8641 | 0.000 |
Why?
|
Adrenal Cortex Hormones | 1 | 1989 | 1870 | 0.000 |
Why?
|